Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories preterm Infant Formula (NEC) Litigation Reserve Balance ($M) ($M)
Form 10-Q / 10-K Litigation Contingencies Footnote
Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q3 2024
Sources
4
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Preterm Infant Formula (NEC) Litigation Reserve Balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 0 | – | SEC Filing (0001628280-26-050134) ↗ |
| Q1 2026 | Mar 31, 2026 | 0 | – | SEC Filing (0001628280-26-028357) ↗ |
| Q1 2025 | Mar 31, 2025 | 0 | – | SEC Filing (0001628280-25-021090) ↗ |
| Q3 2024 | Sep 30, 2024 | 0 | – | SEC Filing (0001628280-26-010185) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Preterm Infant Formula (NEC) Litigation Reserve Balance ($M) ($M), quarterly Q3 2024–Q2 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/ped-nec-lit-res
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.